102.23
-0.55 (-0.54%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ligand Pharmaceuticals Incorpor | Bullish | Bullish |
Stockmoo Score
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Chicago Capital, Llc | 30 Jun 2024 | 514,946 |
| Villere St Denis J & Co /Adv | 30 Jun 2024 | 483,913 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 144.00 (HC Wainwright & Co., 40.86%) | Buy |
| Median | 135.00 (32.06%) | |
| Low | 110.00 (Benchmark, 7.60%) | Buy |
| Average | 131.00 (28.14%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 96.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 12 Aug 2024 | 110.00 (7.60%) | Buy | 99.60 |
| 28 Jun 2024 | 95.00 (-7.07%) | Buy | 84.26 | |
| RBC Capital | 12 Aug 2024 | 130.00 (27.16%) | Buy | 99.60 |
| 30 Jul 2024 | 130.00 (27.16%) | Buy | 110.11 | |
| HC Wainwright & Co. | 08 Aug 2024 | 144.00 (40.86%) | Buy | 96.92 |
| 08 Jul 2024 | 144.00 (40.86%) | Buy | 86.88 | |
| Craig-Hallum | 09 Jul 2024 | 140.00 (36.95%) | Buy | 91.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Sep 2024 | Announcement | Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy |
| 20 Aug 2024 | Announcement | Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference |
| 06 Aug 2024 | Announcement | Ligand Reports Second Quarter 2024 Financial Results |
| 23 Jul 2024 | Announcement | Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 |
| 08 Jul 2024 | Announcement | Ligand to Acquire APEIRON Biologics AG for $100 Million |
| 27 Jun 2024 | Announcement | Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years |
| 18 Jun 2024 | Announcement | Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |